Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with ...
Learn more about whether AnaptysBio, Inc. or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
VANCOUVER, BC / ACCESS Newswire / April 10, 2026 / Arcus Development Group Inc. (TSXV:ADG)("Arcus" or the "Company") is pleased to announce that Eric Negraeff, Jeremy Hanson and Kiya Hushyar have been ...
Arcus and AstraZeneca to evaluate their respective molecules in combination to establish a potential first- and best-in-class treatment for clear cell renal cell carcinoma (ccRCC) This is the second ...
Gilead Sciences and Arcus are slimming down a phase 3 TIGIT trial to compare the lung cancer combo therapy to just Merck’s Keytruda, ditching a chemotherapy arm. The move means a little extra cash ...
At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing ...
Gilead Sciences and Arcus Biosciences said they’ve expanded their three-year-old collaboration. An equity stake in Arcus, board seat for Gilead’s commercial chief and a streamlined immuno-oncology ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
An icon in the shape of a lightning bolt. Impact Link While Arcus CEO Edrizio De La Cruz was studying at the University of Pennsylvania's Wharton Business School, he was also trying to come up with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results